Trial Profile

A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Ilixadencel (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Uterine cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ILIAD
Sponsors Mendus

03 Dec 2021 Results published in the Media Release
03 Dec 2021 According to an Immunicum media release, updated data from this study will be provide in the first quarter of 2022
03 Dec 2021 Status changed from active, no longer recruiting to discontinued, according to an Immunicum media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com